Opinion
Video
ASH 2023: PERSEUS Trial Overview
Rafael Fonseca, MD, discusses findings from the PERSEUS trial presented in December at ASH 2023.
This is a video synopsis/summary of a Post Conference Perspectives featuring Rafael Fonseca, MD.
The PERSEUS trial compared bortezomib, lenalidomide, and dexamethasone (VRd) to lenalidomide, bortezomib, and dexamethasone plus daratumumab (D-VRd) in over 700 newly diagnosed, transplant-eligible multiple myeloma patients. After induction, stem cell transplant, and consolidation with the same regimens, patients in the VRd arm received lenalidomide maintenance while patients in the D-VRd armreceived daratumumab plus lenalidomide. Importantly, minimal residual disease (MRD) testing occurred, allowing therapy discontinuation in sustained MRD-negative complete responders after 2 years.
At 4 years, progression-free survival was 84.3% with D-VRd vs 67.7% with VRd (HR, 0.42), a statistically significant difference. Response rates including complete response and MRD negativity also favored D-VRd. Given the strength of these phase 3 results, D-VRd should be considered for initial induction for transplant-eligible myeloma. Adding daratumumab improves outcomes, including in the maintenance setting, while generic availability makes this affordable globally.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
